#Singapore #Archerfish #Angsana #Pathnova

Archerfish Precision Diagnostics: A New Milestone in Clinical Diagnostics

In a landmark event for the clinical diagnostics sector in Singapore, Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories have united to establish Archerfish Precision Diagnostics Private Limited. This merger signifies a consolidation of expertise from both renowned laboratories, aiming to redefine the landscape of advanced diagnostics in the region.

Bridging Expertise for Comprehensive Diagnostics

The merger combines Angsana’s significant achievements in molecular diagnostics with Pathnova’s strengths in serology and artificial intelligence. This partnership is poised to deliver a broader array of advanced diagnostic assays, addressing both common and complex diseases prevalent in Asia.

Angsana has long been recognized as a pioneer in molecular oncology within Asia, having introduced clinical Next-Generation Sequencing (NGS) early in its journey. With a proven track record, Angsana has successfully commercialized numerous clinical diagnostic tests. On the other hand, Pathnova excels in diagnostic product development and manufacturing, boasting proprietary technologies such as an early screening test for nasopharyngeal cancer.

Vision for Diagnostic Innovation

Archerfish is driven by a vision to lead in diagnostic innovation, ensuring that accurate and timely diagnostic solutions are accessible for early cancer detection and other critical health interventions. By harnessing state-of-the-art technologies and ongoing research, Archerfish aims to expand its portfolio, pushing the boundaries of clinical practice.

Expanding Next-Generation Sequencing (NGS) Applications

One of the pivotal areas Archerfish intends to focus on is enhancing NGS applications beyond personalized cancer care to include infectious disease identification. The integration of metagenomic NGS (mNGS) will allow for comprehensive microorganism identification, thus enabling rapid detection of various viral and bacterial infections from a single plasma sample—further emphasizing the company’s commitment to swift diagnostics.

Data-Driven Disease Detection and AI Integration

The intelligence behind Archerfish's data-driven disease detection is powered by serum proteomics and serological profiling advancements. This cutting-edge technology will enable the detection of thousands of proteins in serum, thus offering versatile tools for various diagnostic issues. Archerfish is also integrating artificial intelligence techniques to refine data analysis, which will enhance the precision of disease detection and predictive capabilities.

Leadership and Strategic Investments

At the helm of Archerfish is a diverse management team consisting of distinguished clinicians, scientists, and experienced healthcare professionals. Their collective expertise in diagnostics, research, and business strategy serves as a driving force for Archerfish’s ambitions in the competitive landscape of Asia’s diagnostics industry.

The merger is supported by a collaborative consortium of strategic investors, which includes notable entities like Temasek Life Sciences Laboratory, The Life Sciences Innovation Fund, and SEEDS Capital. This backing will provide critical funding and support for research and technological advancement, steering Archerfish toward its lofty objectives.

Driving Forward: Collaborations and Future Growth

Archerfish's formation is expected to foster enhanced collaboration within public-private partnerships, contributing to healthcare cost efficiency and improved access to diagnostic services. Plans are underway to seek a minimum of SGD$50 million in funding over the next three years to support the company’s growth and innovation strategies.

Dr. Lim Cheok Peng, Chairman at Archerfish Precision Diagnostics, notes, 'This merger represents a vital leap in our journey to advance diagnostic science, ultimately enhancing patient care.' Similarly, Dr. Ian Cheong, Director at Archerfish, highlights the importance of bridging scientific evidence with effective clinical laboratory solutions.

In summary, the strategic merger of Angsana and Pathnova to form Archerfish Precision Diagnostics marks a pivotal moment in Singapore's clinical landscape, setting a high standard for innovation in diagnostic solutions that aims to benefit both healthcare providers and patients alike.